Karyopharm Therapeutics (NASDAQ:KPTI) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a hold rating to a sell rating in a report released on Saturday morning.

KPTI has been the topic of a number of other reports. HC Wainwright lowered Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research report on Friday, July 31st. Royal Bank Of Canada reissued an “outperform” rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. Weiss Ratings upgraded shares of Karyopharm Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Robert W. Baird lowered shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research note on Friday, July 31st. Finally, Piper Sandler dropped their price objective on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

Karyopharm Therapeutics Price Performance

Shares of KPTI opened at $1.81 on Friday. The stock has a 50-day moving average of $7.33 and a 200-day moving average of $7.83. Karyopharm Therapeutics has a one year low of $1.79 and a one year high of $10.99. The company has a market cap of $41.05 million, a PE ratio of -0.14 and a beta of 0.90.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.37) by ($0.95). The business had revenue of $33.43 million during the quarter, compared to analyst estimates of $32.19 million. Analysts expect that Karyopharm Therapeutics will post -4.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KPTI. Commodore Capital LP purchased a new position in shares of Karyopharm Therapeutics during the first quarter valued at approximately $10,862,000. T. Rowe Price Investment Management Inc. raised its position in Karyopharm Therapeutics by 112.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock valued at $10,977,000 after buying an additional 790,417 shares during the last quarter. Ikarian Capital LLC lifted its stake in Karyopharm Therapeutics by 1,897.9% during the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after acquiring an additional 517,297 shares in the last quarter. Avidity Partners Management LP lifted its stake in Karyopharm Therapeutics by 244.6% during the 1st quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after acquiring an additional 329,175 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Karyopharm Therapeutics by 101.2% during the 4th quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock valued at $1,382,000 after acquiring an additional 94,445 shares in the last quarter. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.